LUNG

Company Overview — What Does Pulmonx Corp Do?

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Pulmonx Corp (LUNG) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Glendon E. French and employs approximately 250 people. With a market capitalization of $54M, LUNG is one of the notable companies in the Healthcare sector.

Pulmonx Corp (LUNG) Stock Rating — Avoid (April 2026)

As of April 2026, Pulmonx Corp receives a Avoid rating with a composite score of 26.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.LUNG ranks #4,227 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Pulmonx Corp ranks #757 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LUNG Stock Price and 52-Week Range

Pulmonx Corp (LUNG) currently trades at $1.37. The stock gained $0.01 (0.7%) in the most recent trading session. The 52-week high for LUNG is $7.96, which means the stock is currently trading -82.8% from its annual peak. The 52-week low is $1.31, putting the stock 4.6% above its annual trough. Recent trading volume was 194K shares, suggesting relatively thin trading activity.

Is LUNG Overvalued or Undervalued? — Valuation Analysis

Pulmonx Corp (LUNG) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.00x, versus the sector average of 2.75x. The price-to-sales ratio is 0.61x, compared to 1.66x for the average Healthcare stock.

At current multiples, Pulmonx Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Pulmonx Corp Profitability — ROE, Margins, and Quality Score

Pulmonx Corp (LUNG) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -106.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -44.6% versus the sector average of -33.1%.

On a margin basis, Pulmonx Corp reports gross margins of 73.2%, compared to 71.5% for the sector. The operating margin is -65.7% (sector: -66.1%). Net profit margin stands at -65.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 3.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LUNG Debt, Balance Sheet, and Financial Health

Pulmonx Corp has a debt-to-equity ratio of 69.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 5.07x, indicating strong short-term liquidity. Total debt on the balance sheet is $37M. Cash and equivalents stand at $77M.

LUNG has a beta of 0.93, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Pulmonx Corp is 25/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Pulmonx Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, Pulmonx Corp reported revenue of $88M and earnings per share (EPS) of $-1.33. Net income for the quarter was $-58M. Gross margin was 73.2%. Operating income came in at $-58M.

In FY 2025, Pulmonx Corp reported revenue of $90M and earnings per share (EPS) of $-1.33. Net income for the quarter was $-54M. Gross margin was 74.2%. Revenue grew 8.0% year-over-year compared to FY 2024. Operating income came in at $-54M.

In Q3 2025, Pulmonx Corp reported revenue of $22M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-14M. Gross margin was 74.7%. Revenue grew 5.5% year-over-year compared to Q3 2024. Operating income came in at $-14M.

In Q2 2025, Pulmonx Corp reported revenue of $24M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-15M. Gross margin was 72.1%. Revenue grew 14.8% year-over-year compared to Q2 2024. Operating income came in at $-15M.

Over the past 8 quarters, Pulmonx Corp has demonstrated a growth trajectory, with revenue expanding from $21M to $88M. Investors analyzing LUNG stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LUNG Dividend Yield and Income Analysis

Pulmonx Corp (LUNG) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LUNG Momentum and Technical Analysis Profile

Pulmonx Corp (LUNG) has a momentum factor score of 14/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

LUNG vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Pulmonx Corp (LUNG) ranks #757 out of 838 stocks based on the Blank Capital composite score. This places LUNG in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LUNG against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LUNG vs S&P 500 (SPY) comparison to assess how Pulmonx Corp stacks up against the broader market across all factor dimensions.

LUNG Next Earnings Date

No upcoming earnings date has been announced for Pulmonx Corp (LUNG) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LUNG? — Investment Thesis Summary

The quantitative profile for Pulmonx Corp suggests caution. The quality score of 32/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 14/100, a headwind for near-term performance. High volatility (stability score 25/100) increases portfolio risk.

In summary, Pulmonx Corp (LUNG) earns a Avoid rating with a composite score of 26.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LUNG stock.

Related Resources for LUNG Investors

Explore more research and tools: LUNG vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LUNG head-to-head with peers: LUNG vs AZN, LUNG vs SLGL, LUNG vs VMD.